BioSpace News Archive

Maui Derm for Dermatologies 2020 Meeting is being held from January 25-29, 2020, in Maui Hawaii

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced that the ongoing Phase 2a BALANCED study of AKR-001 is being expanded to include an additional cohort of subjects with NASH who have compensated cirrhosis (F4), Child-Pugh Class A.

InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its results for the fourth quarter and full year 2019 before the Nasdaq market opens on Tuesday, February 18, 2020.

Avitide Inc., the industry leader in the discovery and development of custom affinity purification resins, announce a partnership expansion with Allergan.

Curis, Inc (NASDAQ: CRIS) and DarwinHealth, Inc. today announced a multi-year scientific research collaboration to use quantitative, systems biology-based algorithms, CLIA-approved technologies, and novel, validated approaches focused on Master Regulator (MR) proteins and tumor checkpoint

Blueprint Medicines Corporation announced corporate goals for 2020, which provide a path to achieve the company’s “2020 Blueprint” strategy for launching its global commercial business.

Dovetail Genomics, the industry leader in advanced proximity ligation genomic solutions, today announced an expanded Genome Assembly offering through its best-in-class genome assembly services, leveraging its Omni-C Technology, which provides unparalleled uniformity per-base genome coverage

Accuray Incorporated (Nasdaq: ARAY) will be discussing its business and revenue growth expectations for the next three fiscal years at the JP Morgan Healthcare Conference on Wednesday, January 15, 2020 at 10:00 am PACIFIC / 1:00 pm EASTERN.

Titan Pharmaceuticals, Inc. announced that it has signed an agreement for Probuphine implant to be included on the Federal Supply Schedule, providing U.S. veterans and other federal government agencies with access to Titan’s novel 6-month maintenance treatment for Opioid Use Disorder in eligible patients.

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced preliminary financial results for the fourth quarter and full year 2019 and provided 2020 financial guidance.